Advertisement

International Journal of Clinical Oncology

, Volume 23, Issue 4, pp 652–658 | Cite as

Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma

  • Toshifumi Yamaguchi
  • Ken Kato
  • Kengo Nagashima
  • Satoru Iwasa
  • Yoshitaka Honma
  • Atsuo Takashima
  • Tetsuya Hamaguchi
  • Yoshinori Ito
  • Jun Itami
  • Narikazu Boku
  • Kazuhide Higuchi
Original Article

Abstract

Background

While the standard treatment for stage II–III (non-T4) esophageal squamous cell carcinoma (ESCC) is neoadjuvant therapy followed by esophagectomy, definitive chemoradiation therapy (dCRT) is an option to treat ESCC patients who reject or may not tolerate surgical treatment. Second primary malignancy (SPM) is a problem for long-term survivors after achieving complete response (CR) by dCRT.

Methods

The source of the subjects in this study was the patients with stage II/III (excluding T4 disease) ESCC (UICC6th) who underwent dCRT from 2000 to 2011 at the National Cancer Center Hospital, Japan. SPM, defined as malignancy newly detected at different site from the initial disease, was checked in patients who achieved CR by the initial dCRT.

Results

Among the 285 patients with stage II/III (excluding T4 disease) ESCC who underwent dCRT, 185 patients achieved CR. SPM was detected in 49 patients (median time to developing SPM, 41.5 months), accounting for 19.3% (95% CI 0.137–0.257) as the 5-year cumulative risk of SPM. SPMs were head and neck cancer (n = 12), gastric cancer (n = 12), esophageal cancer (n = 7), lung cancer (n = 5), colon cancer (n = 4), diffuse large B-cell lymphoma (n = 3), bladder cancer (n = 2), small intestinal cancer (n = 1), cholangiocarcinoma (n = 1), malignant melanoma (n = 1), and breast cancer (n = 1). There were no significant differences in baseline characteristics between the patients who developed SPM (n = 49) and others (n = 136).

Conclusions

Because second primary malignancy developed often after achieving CR by dCRT for ESCC, it should be followed carefully.

Keywords

Esophageal cancer Second primary malignancy Chemoradiation 

Notes

Compliance with ethical standards

Conflict of interest

None of the authors have conflicts of interest to declare.

References

  1. 1.
    Tachimori Y, Ozawa S, Numasaki H et al (2016) Comprehensive registry of esophageal cancer in Japan, 2009. Esophagus 13:110–137CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20(5):1167–1174CrossRefPubMedGoogle Scholar
  3. 3.
    Conroy T, Galais MP, Raoul JL et al (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15:305–314CrossRefPubMedGoogle Scholar
  4. 4.
    Kato K, Muro K, Minashi K et al (2011) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 81:684–690CrossRefPubMedGoogle Scholar
  5. 5.
    Kato K, Nakajima TE, Ito Y et al (2013) Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II–III esophageal carcinoma. Jpn J Clin Oncol 43:608–615CrossRefPubMedGoogle Scholar
  6. 6.
    Shinoda M, Ando N, Kato K et al (2015) Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 106(4):407–412CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Steevens J, Schouten LJ, Goldbohm RA et al (2010) Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut 59(1):39–48CrossRefPubMedGoogle Scholar
  8. 8.
    Sakata K, Hoshiyama Y, Morioka S et al (2005) Smoking, alcohol drinking and esophageal cancer: findings from the JACC Study. J Epidemiol 15:S212–S219CrossRefPubMedGoogle Scholar
  9. 9.
    Ishiguro S, Sasazuki S, Inoue M et al (2009) Effect of alcohol consumption, cigarette smoking and flushing response on esophageal cancer risk: a population-based cohort study (JPHC study). Cancer Lett 275(2):240–246CrossRefPubMedGoogle Scholar
  10. 10.
    Secretan B, Straif K, Baan R et al (2009) A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 10(11):1033–1034CrossRefPubMedGoogle Scholar
  11. 11.
    Cui R, Kamatani Y, Takahashi A et al (2009) Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology 137(5):1768–1775CrossRefPubMedGoogle Scholar
  12. 12.
    Yokoyama T, Yokoyama A, Kato H et al (2003) Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squamous cell carcinoma in Japanese men. Cancer Epidemiol Biomarkers Prev 12(11 Pt 1):1227–1233PubMedGoogle Scholar
  13. 13.
    Sudo K, Xiao L, Wadhwa R et al (2014) Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 32(30):3400–3405CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Japan Esophageal Society (2009) Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus 6:71–94CrossRefGoogle Scholar
  15. 15.
    Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. JASA 94(446):496–509CrossRefGoogle Scholar
  16. 16.
    Matsubara T, Yamada K, Nakagawa A et al (2003) Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21(23):4336–4341CrossRefPubMedGoogle Scholar
  17. 17.
    Sato Y, Motoyama S, Maruyama K et al (2005) A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg 201(2):188–193CrossRefPubMedGoogle Scholar
  18. 18.
    Braakhuis BJ, Tabor MP, Leemans CR et al (2002) Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 24(2):198–206CrossRefPubMedGoogle Scholar
  19. 19.
    Kaur P, Bansal N, Kumar JV et al (2016) A retrospective evaluation of clinical profile of second primary head and neck cancer. J Clin Diagn Res 10(10):XC10–XC14PubMedGoogle Scholar
  20. 20.
    Katada C, Yokoyama T, Yano T et al (2016) Alcohol consumption and multiple dysplastic lesions increase risk of squamous cell carcinoma in the esophagus, head, and neck. Gastroenterology 151(5):860–869CrossRefPubMedGoogle Scholar
  21. 21.
    Jégu J, Colonna M, Daubisse-Marliac L et al (2014) The effect of patient characteristics on second primary cancer risk in France. BMC Cancer 15(14):94CrossRefGoogle Scholar
  22. 22.
    Wu GX, Nelson RA, Kim JY et al (2017) Non-small cell lung cancer as a second primary among patients with previous malignancy: who is at risk? Clin Lung Cancer 18(5):543–550CrossRefPubMedGoogle Scholar
  23. 23.
    Nandy N, Dasanu CA et al (2013) Incidence of second primary malignancies in patients with esophageal cancer: a comprehensive review. Curr Med Res Opin 29(9):1055–1065CrossRefPubMedGoogle Scholar
  24. 24.
    Chose KS, Haraf DJ, Solanki A et al (2011) Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer 117(20):4671–4678CrossRefGoogle Scholar
  25. 25.
    Razavi P, Rand KA, Cozen W et al (2013) Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J 3:121CrossRefGoogle Scholar
  26. 26.
    Lemieux MH, Solanki AA, Mahmood U et al (2015) Risk of second malignancies in patients with early-stage classical Hodgkin’s lymphoma treated in a modern era. Cancer Med 4(4):513–518CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ailawadhi S, Swaika A, Razavi P et al (2014) Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups. Blood Cancer J 4:243CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2018

Authors and Affiliations

  • Toshifumi Yamaguchi
    • 1
    • 2
  • Ken Kato
    • 3
  • Kengo Nagashima
    • 5
  • Satoru Iwasa
    • 3
  • Yoshitaka Honma
    • 3
  • Atsuo Takashima
    • 3
  • Tetsuya Hamaguchi
    • 6
  • Yoshinori Ito
    • 4
  • Jun Itami
    • 4
  • Narikazu Boku
    • 3
  • Kazuhide Higuchi
    • 2
  1. 1.Cancer Chemotherapy Center, Osaka Medical College HospitalOsaka Medical CollegeTakatsukiJapan
  2. 2.Second Department of Internal MedicineOsaka Medical CollegeTakatsukiJapan
  3. 3.Gastrointestinal Oncology DivisionNational Cancer Center HospitalTokyoJapan
  4. 4.Radiation Oncology DivisionNational Cancer Center HospitalTokyoJapan
  5. 5.Department of Global Clinical Research, Graduate School of MedicineChiba UniversityChibaJapan
  6. 6.Department of Gastrointestinal OncologySaitama Medical University International Medical CenterHidakaJapan

Personalised recommendations